Filters
Antibiotic resistance genes (ARGs)—DNA segments that enable bacterial survival in the presence of antibiotics— can be detected in newborns’ meconium shortly after birth, as shown in a study presented at ESCMID Global 2026.
An observational study shows an association between adjunctive clindamycin and reduced odds of mortality in children with invasive Group A streptococcal (iGAS) infections.
Among patients hospitalized with severe SARS-CoV-2 infection, acute-phase systemic corticosteroid exposure is associated with greater odds of long COVID symptoms, according to a study.
A study presented at ESPID 2026 demonstrates an association between respiratory syncytial virus (RSV) infection and an increased risk of childhood asthma.
Administering influenza vaccine concomitantly with pertussis-containing vaccine during pregnancy does not contribute to increased risk of adverse pregnancy outcomes, as reported in a retrospective study.
New drug applications approved by US FDA as of 16-31 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.
The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.
Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.